Feb 10, 2019
Approved in May 2018, Andexxa is the first and only available agent indicated for the reversal of the direct oral anticoagulants (DOACs). Previously, many health systems relied on the off-label use of the much less costly 4F-PCC.
Given its high cost, should hospital pharmacies add Andexxa to formulary for the reversal of DOACs during emergent bleeding?
Download this PDF for the Lumere team’s analysis of the evidence.
Watch a related video: Drug and Device Insights: Does the Evidence Support Andexxa’s Price Premium?
© Lumere All rights reserved